The central theme of personalized medicine is the premise that an individual's unique
physiologic characteristics play a significant role in both disease vulnerability and in …

Abstract Second-generation antipsychotics (SGAs), such as risperidone, clozapine and
olanzapine, are the most common drug treatments for schizophrenia. SGAs presented an …

Psychostimulant, cardiovascular, and temperature actions of stimulants involve adrenergic
(norepinephrine), dopaminergic (dopamine), and serotonergic (serotonin) pathways …

Objective: To provide an overview for practicing clinicians on the pharmacological basis of
cardiometabolic risk induced by antipsychotic drugs in patients with serious mental illness …

The prevalence of overweight and obesity is higher in people with mental illness than in the
general population. Body weight is tightly regulated by a complex system involving the …

This review examines the pharmacology of stimulants prohibited by the World Anti‐Doping
Agency (WADA). Stimulants that increase alertness/reduce fatigue or activate the …

Objective: During the past decades, increasing efforts have been invested in studies to
unravel the influence of genetic factors on antipsychotic (AP) dosage, treatment response …

The second generation antipsychotics clozapine and olanzapine frequently induce weight
gain. Randomized studies investigating abnormal eating behavior (food craving, binge …

Developed countries around the world are experiencing an epidemic of overeating and
obesity with significant costs at a personal, familial, and societal level. While most research …

Antipsychotic therapy forms the cornerstone of treatment for people with severe mental
illness. Second-generation (atypical) antipsychotics are associated with a significantly lower …